HUTCHMED (China) Limited received conditional approval from China’s National Medical Products Administration for ATLED, its oral fanregratinib treatment for a defined group of adult intrahepatic cholangiocarcinoma patients. The decision covers advanced, metastatic or unresectable disease with FGFR2 fusions or rearrangements after prior systemic therapy. …
Each ADS represents 500 ordinary shares. The pre-funded warrant exercise price is $0.0001 per ADS, meaning KAZIA THERAPEUTICS LTD (NASDAQ: KZIA) expects little additional cash from those exercises.
MediWound Ltd. (NASDAQ: MDWD) identifies HOLD Alapkezelo Zrt. As the beneficial owner of 1,348,323 common shares, representing approximately 10.4% of the company’s common stock. The position is covered by an amended Schedule 13G/A dated August 27.
Cardiff Oncology, Inc. (NASDAQ: CRDF) will ask shareholders on October 22, 2026, to approve an amendment increasing authorized capital stock from 170,000,000 to 320,000,000 shares. The same measure would increase authorized common stock from 150,000,000 to 300,000,000 shares. A second proposal would allow the …
CITIUS ONCOLOGY, INC. (NASDAQ: CTOR) will hold its annual stockholder meeting on September 29, with three Class II director seats up for election.
Alto Neuroscience, Inc. (NYSE: ANRO) promoted Chief Financial Officer and ChiefBusinessOfficer Nicholas C. Smith to President and Chief Financial Officer effective August 26, 2026. The promotion makes Smith eligible for a $6,000,000 retention payment, while Amit Etkin continues as Chief Executive Officer.
Availability is expected in U.S. pharmacies, hospitals and clinics in the coming days.
Candor Therapeutics Inc. is pursuing a $750,000 exempt securities offering under a Simple Agreement for Future Equity, with $50,000 sold so far. Investors can see that $700,000 of the stated offering amount remains available, providing the clearest disclosed measure of the financing still to …
Mariano Gomide de Faria, Chief Executive Officer of VTEX (NYSE:VTEX), filed a Form 4 on August 28, 2026, disclosing transactions in Class A Common Shares dated August 26, 2026, including the conversion of restricted stock units and the withholding of shares to cover tax …
A statement of changes in beneficial ownership filed on August 28, 2026 disclosed that Scott Reese, a director of Keysight Technologies, Inc., acquired 435 shares of common stock through an immediately vesting restricted stock unit grant on August 26, 2026.